Drug Therapy for Diabetes Mellitus. Adj A/Prof Daniel Chew Dept of Endocrinology 8 th July 2017

Similar documents
Comprehensive Diabetes Treatment

Diabetes Mellitus II CPG

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Dept of Diabetes Main Desk

Insulin Initiation and Intensification. Disclosure. Objectives

The Many Faces of T2DM in Long-term Care Facilities

Glucose Control drug treatments

Overview T2DM medications. Winnie Ho

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Diabetes Mellitus case studies. Jana Vinklerová

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

Oral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Professor Rudy Bilous James Cook University Hospital

There have been important changes in diabetes care which may not be covered in undergraduate textbooks.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

Newer Drugs in the Management of Type 2 Diabetes Mellitus

NEW DIABETES CARE MEDICATIONS

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

STEP 3: Add or Substitute with one of

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

The Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center

COPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?

Early treatment for patients with Type 2 Diabetes

Diabetes, Type 2 Management

3. Cardiovascular Disease?

Chief of Endocrinology East Orange General Hospital

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Mr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)

Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period

Type 2 diabetes: recent advances in diagnosis and management

What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital

DIABETES INDICATIONS FOR INSULIN

Arrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol

PERIOPERATIVE DIABETES GUIDELINE

Current principles of diabetes management

How they work and when to take them. Diabetes Medications

Drug Class Monograph

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

Vipul Lakhani, MD Oregon Medical Group Endocrinology

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

Wayne Gravois, MD August 6, 2017

sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS

Inpatient Diabetes 20/01/2015. What should I do? Hyperglycaemia why does it matter? Why are the BSLs unstable? BSL parameters

Dr Karen McNeil Consultant Endocrinologist

Dr A Pokrajac MD MSc MRCP Consultant

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures

I. General Considerations

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

Drugs used in Diabetes. Dr Andrew Smith

DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration

Insulin Prior Authorization with optional Quantity Limit Program Summary

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine

SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION

Diabetes mellitus. Treatment

Medical therapy advances London/Manchester RCP February/June 2016

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Pharmacological Glycaemic Control in Type 2 Diabetes

Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University

Initiating Injectable Therapy in Type 2 Diabetes

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

Diabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy

CASE A2 Managing Between-meal Hypoglycemia

Dr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?

Clinical Practice Guidelines

What s New on the Horizon: Diabetes Medication Update

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

GLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.

OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION

How can we improve outcomes in Type 2 diabetes?

DIABETES UPDATE 2018

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs

Advanced Practice Education Associates. Endocrine

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Intensification of Diabetic Therapy. Case studies

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

What s New in Diabetes Medications. Jena Torpin, PharmD

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Combination treatment for T2DM

Management of Diabetes

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Cardiovascular Management of a Patient with Diabetes

Physiology of Normoglycemia

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Insulin Therapy Management. Insulin Therapy

PLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:

Transcription:

Drug Therapy for Diabetes Mellitus Adj A/Prof Daniel Chew Dept of Endocrinology 8 th July 2017

Diabetes Subtypes Optimal Treatment

Ominous Octet DeFronzo. DIABETES, VOL. 58, APRIL 2009

Schematic Overview of Pathogenesis of Diabetic Complications Physiol Rev 93: 137 188, 2013

Cumulative Mortality median of 7.9 years of gain of life Diabetologia online 16 th August 2016

Cumulative Incidence of the composite CV or Death Endpoint median of 8.1 years of CV free Diabetologia online 16 th August 2016

Summary of studies examining the effect of sulfonylurea (SU) treatment DeFronzo. DIABETES, VOL. 58, APRIL 2009

Elements of Decision Making

ADA Guidelines: Antiglycemic Treatment in T2DM American Diabetes Association. Diabetes Care 2017

Other Considerations when deciding on Diabetes Medications Care Setting Outpatient long - term considerations Inpatient acute illness - sepsis, AoCKD, NBM Peri-operative DM in pregnancy

Insulin Hexamer ZINC Monomer Monomer

Types of Insulin Basal Supplements Premeal Bolus rdna Human insulin NPH Humulin N or Insulatard OR Insulin Analogs Glargine + (Lantus) Determir * (Levemir) + Shifted Isoelectric point rdna Human insulin Regular Humulin R or Actrapid OR Insulin Analogs Lispro (Humalog) Aspart (Novorapid) Glulisine (Apidra) * Binding to Albumin Non-Hexameric insulin analogs

Serum Insulin levels To Replicate Physiological Insulin Secretion Hormonal Nadir Dawn Phenomenon 6u 6u 6u Basal Secretion (Approx 1 unit/hr = 24 units/day) BF Lunch Dinner 10pm 4am * 70kg with minimal insulin resistance

Treating fasting hyperglycaemia lowers the entire 24-hour plasma glucose profile Plasma glucose (mg/dl) 400 300 200 100 0 Meal Meal Meal 0 06.00 10.00 14.00 18.00 22.00 02.00 06.00 Time of day (hours) Nocte NPH or LA Basal Analogue T2DM Hyperglycaemia due to an increase in fasting glucose Normal 20 15 10 5 Plasma glucose (mmol/l) Comparison of 24-hour glucose levels in control subjects vs patients with diabetes (p<0.001). Adapted from Hirsch I, et al. Clin Diabetes 2005;23:78 86.

Insulin Requiring Diabetes Marked hyperglycemia Rapid onset of severe symptoms Significant weight loss Ketoacidosis Type 1 or Type 2 with severe concurrent illness or glucotoxicity < 30 years of age at presentation Lean (No metabolic syndrome/acanthosis nigricans) To exclude Type 1 Diabetes Mellitus Immune markers Eg Anti-GAD, Islet cell Ab Low C-peptide reserves 19

Metformin Important insulin sensitiser Recommended doses 1500-2500mg/day Renal Clearance Unmetabolised Contraindicated Renal ( Creat 150umol/L, <30ml/min* ) Hepatic, Cardiac failure, Alcohol abuse Sepsis and hypoperfusion Cautious use in elderly, anorexic GI Intolerance Interferes with Vitamin B12 absorption *Diabet Med 24:1160 1163, 2007

Biologic Effect of Primary Drug Hepatic Metabolism? Or Renal Excretion? Active Metabolites?

Incretins GLP-1 Receptor Agonists S/C Exenatide BD S/C Liraglutide OM (97%homology+FA) Dipeptidyl peptidase IV (DPP-IV) Inhibitors Sitagliptin Vildagliptin Saxagliptin Linagliptin, etc

Benefits of Incretins Effectively reduces HbA1c Reduced food intake and weight loss (With incretin analogues) Glucose-dependent insulinotropic effect Glucose-dependent inhibition of elevated plasma glucagon levels

PANCREATIC BETA CELL GLP-1R GIPR ATP/ADP Modified, Diabetes 51 (Suppl. 1):S19 S24, 2002

Basal insulin added to GLP-1 receptor agonist: LIRA-DETEMIR study design Open-label randomisation (1:1) Continue MET + liraglutide 1.8 mg (Control group) Main study n=161; extension n=122 Addition of insulin detemir to MET + liraglutide Main study n=162; extension n=140 Patients with suboptimal control on MET SU Addition of liraglutide 1.8 mg to MET HbA 1c 7% 39% Main study 26 weeks Extension 26 weeks 12-week run-in phase HbA 1c <7% 61% Continue MET + liraglutide 1.8 mg (Observational group) Main study n=498; extension n=461 MET, metformin; SU, sulphonylurea DeVries JH et al. Diabetes Care 2012;35:1446 1454

HbA 1c (%) Addition of insulin detemir to liraglutide: Change in HbA 1c (%) Run-in phase Randomised phase (Weeks 0 to 52) 8.5 Time (weeks) 12 8 4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 8.0 7.5 7.0 +0.01 p<0.0001 0.50 6.5 6.0 Liraglutide 1.8 mg Liraglutide 1.8 mg + IDet Observational liraglutide 1.8 mg Mean (2SE); data are LOCF Last observation before intensification is included as LOCF in the initial treatment group; ANCOVA on FAS LOCF for difference in randomised phase ANCOVA, analysis of covariance; FAS, full analysis set; HbA 1c, glycosylated haemoglobin; IDet, insulin detemir; LOCF, last observation carried forward; SE, standard error Rosenstock J et al. J Diabetes Complications 2013;27:492 500

What is the Relation? Phlorizin Apple Tree Proximal Tubule Epithelial Cell

Comparing SGLT2 - Inhibitors

SGLT2 Inhibitors: gliflozin Works independently of insulin Inhibiting the SGLT2 glucose transporter found in proximal tubule of nephron, responsible for glucose reabsorption Dose-dependant renal glycosuria, lowering both plasma glucose levels and insulinemia Reductions in HbA1c 0.7% Reductions in Total Body Weight 2 to3 %

SGLT2 Inhibitors: gliflozin Reduced CVD events and mortality Greater risk of amputation: toe or metatarsal (Canagliflozin)* Risk volume depletion and hypotension: Caution with severe hyperglycemia, concurrent diuretics, acute illness Normoglycemic DKA: Concurrent illness, stress/counter regulatory hormones *DOI: 10.1056/NEJMoa1611925

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors Keep high index of suspicion: Check ph, Serum Bicarbonate and serum BHB Ogawa and Sakaguchi Doi: 10.1111/jdi.12401

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes N Engl J Med 2016;375:323-34

Case Study 1 Mr T 75 year old Chinese Male Strong family history of T2DM T2DM since 50years old Hypertension Ex-smoker PO Glipizide 15mg BD PO Metformin 850mg BD HbA1c 7.5%, Creatinine 80 umol/l Urine microalbumin +ve, Early DM retinopathy

HbA1c above target range * Check for: A. Episodes of hypoglycaemia B. Compliance to anti-diabetic medications (including extent of non compliance) C. Compliance to medical nutrition therapy (including extent of non compliance) D. Weight trend - Weight gain due to hypoglycaemia and hunger. Reductions in the dose of SU and insulin may in fact paradoxically improve the glucose control. - Weight loss (>5-10% of body weight) and a high HbA1c (>9%) are likely insulinopenic and should be started on insulin E. Presence of other medications or medical conditions that can change blood glucose control (e.g. glucocorticoids, inter-current infection, cancer). F. Intensify or alter non-pharmacological therapy (i.e. nutrition therapy, exercise, pharmacotherapy) based on cause(s) identified. G. Start and/or optimize dose of pharmacological therapy *When interpreting the HbA1c, the following should be taken into account: (A) Conditions that may falsely elevate or lower HbA1c (e.g. blood loss, recent blood transfusion or haemoglobinopathies). (B) The HbA1c may not fully reflect blood glucose levels for changes that have taken place less than 3 months before the HbA1c.

Case Study 1 Decreased PO Glipizide 5mg BD Maintained PO Metformin 850mg BD Regular meal times + Light Supper HbA1c 6.7% - 6.8% No hypoglycemia symptoms or documented KIV switch the sulphonylurea to a DPP4 inhibitor

HbA1c at or below target range 1 Check for: (A) Episodes of hypoglycaemia (B) Compliance to anti-diabetic medications (including extent of non compliance) (C) Weight trend 2 - Weight gain due to hypoglycaemia and hunger. Reductions in the dose of SU and insulin may in fact paradoxically improve the glucose control. Consider deescalating insulin or SU (or other OHGAs) if any of the following are present: 1. Episodes of hypoglycaemia 2. HbA1c is at target despite significant non-compliance to medications 3. HbA1c is below target range *When interpreting the HbA1c, the following should be taken into account: (A) Conditions that may falsely elevate or lower HbA1c (e.g. blood loss, recent blood transfusion or haemoglobinopathies). (B) The HbA1c may not fully reflect blood glucose levels for changes that have taken place less than 3 months before the HbA1c.

Case Study2 : 54 year old Male T2DM for 10 years Strong family history of DM & IHD, BMI 30.1 kg/m2 Fasting Glucose 9.8 mmol/l, HbA1c 9.2-10.1% PO Glipizide 5mg BD PO Sitagliptin/Metformin 50mg/1000mg BD PO Acarbose 50mg TDS egfr > 60, Urine ACR +ve, No macrovascular Cx. Diet and Exercise as best as can be No hypoglycemia 1. Add an SGLT2 Inhibitor 2. Initiate Basal Insulin Stop Acarbose 3. Initiate Basal Insulin KIV add SGLT2 Inhibitor or GLP-1 agonist 4. Initiate Basal Bolus 38

Summary Establish Glycaemic Targets Individualise Treatment Use Metformin as the cornerstone of diabetes treatment in T2DM Consider degree of hyperglycemia, risk of hypoglycemia, renal function and other comorbidities in the selection of Rx Timely Insulinisation

Summary SGLT2 Inhibitors for patients at risk of hypoglycemia, cardiovascular and renal benefits but increased risk of genitourinary infections and normoglycemic DKA - synergise well with insulin treatment New formulations of long acting basal analogue insulin eg Glargine 300 Units/ml, Insulin Degludec GLP1 Agonists and Long Acting Basal Insulin combinations

Ideal Diabetic Medication Effective in lowering glucose No or Low risk of hypoglycemia Positive extraglycemic effects Weight Lipid profile Blood Pressure Safe, Tolerable, Ease of use Low Cost / Expense Ability to maintain glucose levels close to non-diabetic range Surrogate Markers HbA1c Lipids Reduce long term microvascular and macrovascular complications - Endpoints

Useful References AACE/ACE Comprehensive Diabetes Manangement Algorithm 2015: ENDOCRINE PRACTICE Vol 21 No. 4 April 2015 ADA/EASD Standards of Care Oral Glucose-lowering Agents in Type 2 Diabetes Mellitus An update Appropriate Care Guide: MOH & ACE Published 3 rd July 2017

Daniel_Chew@ttsh.com.sg